Journals / Haydarpaşa Numune Medical Journal / 2018 / Cilt: 58 - Sayı: 3

Evaluation of Endometrial Changes with Transvaginal Power Doppler Ultrasound and Comparing Them with Endometrial Sampling in Breast Cancer Patients Using Tamoxifen

Pages
137–141
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Moreover, it is not useful in determining which patients require invasive intervention.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: The most unwanted complication of tamoxifen is the development of endometrial carcinoma.
📊
Key Findings & Data:Endometrial sampling was recommended to patients whose endometrial thickness was over 5 mm and was done in 73 patients.
💡
Conclusion & Impact:Moreover, it is not useful in determining which patients require invasive intervention.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Introduction: The most unwanted complication of tamoxifen is the development of endometrial carcinoma. In this study, we used transvaginal power Doppler ultrasound to determine endometrial vascular changes and compared them with the results of endometrial sampling. The diagnostic value of transvaginal power Doppler ultrasound was examined. Methods: One hundred eleven breast cancer patients were included in the study. Endometrial, uterine, adnexal, and vascular evaluations were performed. Endometrial sampling was recommended to patients whose endometrial thickness was over 5 mm and was done in 73 patients. Results: Group 1 (n=62) consisted of patients receiving tamoxifen and group 2 (n=49) consisted of patients who were not using tamoxifen. There were four endometrial polyps (5.5%) in the sample results in Group 2. Twenty patients (14 tamoxifen using and 6 non-tamoxifen using) had abnormal vascular changes on power Doppler examination but none of them had any malignant changes. There were abnormal vascular patterns on power Doppler examination in all of the patients detected with endometrial polyps. Three of them had benign measurable Doppler flow characteristics while one of them had non-measureable flows. All of the patients detected to have an endometrial polyp were pre-menopausal and did not use tamoxifen. Discussion and Conclusion: Transvaginal power Doppler ultrasound is an effective method for determining vascular changes in the endometrium. However, it is not enough for defining the lesion accurately in breast cancer patients. Moreover, it is not useful in determining which patients require invasive intervention.

🔖

Cite This Article

SAKİN, Ö., KARS, B., ÜNAL, O., ŞİMŞEK, E. E., KAŞIKÇI, H. Ö., PİRİMOĞLU, Z. M., ANGIN, A. D., ÇIKMAN, M. S. (2018). Evaluation of Endometrial Changes with Transvaginal Power Doppler Ultrasound and Comparing Them with Endometrial Sampling in Breast Cancer Patients Using Tamoxifen. Haydarpaşa Numune Medical Journal, Cilt: 58 - Sayı: 3, 137–141. https://ajindex.com/articles/198204

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017
  2. 7–30. [CrossRef ] 2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015
  3. 87–108. 3. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomarkers Prev 2016
  4. 16–27. [CrossRef ] 4. Crew KD, Albain KS, Hershman DL, Unger JM, Lo SS. How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer 2017
  5. Rosell J, Nordenskjöld B, Bengtsson NO, Fornander T, Hatschek T, Lindman H, et al. Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen. Acta Oncol 2017
  6. 614–7. 6. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996
  7. 32A:1464–76. [CrossRef ] 7. Kabil Kucur S, Temizkan O, Atis A, Gozukara I, Uludag EU, Agar S, et al. Role of endometrial power Doppler ultrasound using the international endometrial tumor analysis group classification in predicting intrauterine pathology. Arch Gynecol Obstet 2013
  8. 649–54. [CrossRef ] 8. Cohen I, Beyth Y, Azaria R, Flex D, Figer A, Tepper R. Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients. BJOG 2000
  9. 1083–7. [CrossRef ] 9. Achiron R, Grisaru D, Golan-Porat N, Lipitz S. Tamoxifen and the uterus: an old drug tested by new modalities. Ultrasound Obstet Gynecol 1996
  10. 374–8. [CrossRef ] 10. Alcazar JL, Galvan R. Three-dimensional power Doppler ultrasound scanning for the prediction of endometrial cancer in women with postmenopausal bleeding and thickened endometrium. Am J Obstet Gynecol 2009
  11. e1–6. [CrossRef ] 11. Opolskiene G, Sladkevicius P, Valentin L. Prediction of endometrial malignancy in women with postmenopausal bleeding and sonographic endometrial thickness ≥ 4.5 mm. Ultrasound Obstet Gynecol 2011
  12. 232–40. [CrossRef ] 12. de Kroon CD, Hiemstra E, Trimbos JB, Jansen FW. Power Doppler area in the diagnosis of endometrial cancer. Int J Gynecol Cancer 2010
  13. 1160–5. [CrossRef ] 13. Dueholm M, Møller C, Rydbjerg S, Hansen ES, Ørtoft G. An ultrasound algorithm for identification of endometrial cancer. Ultrasound Obstet Gynecol 2014
  14. 557–68. [CrossRef ] 14. Epstein E, Van Holsbeke C, Masci